Advertisement

Topics

UK reimbursement setback for Tecentriq comes with a silver lining

08:53 EDT 2 Aug 2017 | thePharmaLetter

The UK’s health technology assessor has issued draft guidance not recommending Roche’s immunotherapy

Original Article: UK reimbursement setback for Tecentriq comes with a silver lining

NEXT ARTICLE

More From BioPortfolio on "UK reimbursement setback for Tecentriq comes with a silver lining"

Quick Search
Advertisement